Cardiotoxicity | Cyprotex

Archive for the ‘Cardiotoxicity’ Category

The Future of Microelectrode Array (MEA) in Early Toxicology Assessment

Drug safety issues are a major cause of late stage attrition and the pharmaceutical industry is now […]

Read more...

Storms and Science – Delegates Brave the Weather to attend our Novel Advances in Disease Modeling and Toxicology Event

Well it wasn’t a good start to the day – storms hit Boston the night before with […]

Read more...

The Value of Human iPSC-derived Cardiomyocytes and MEA for the Detection of Chronic Cardiac Liabilities

Many of the in vitro assays for evaluating cardiac liability are based on the prediction of proarrhythmias […]

Read more...

Using Cardiac 3D Microtissue Models to determine Functional and Structural Cardiotoxicants

One major cause of attrition in drug discovery and development is cardiotoxicity, which can be a consequence […]

Read more...

In vitro cardiotoxicity assay using MEA

An In-depth Analysis of BMS-986094 Cardiotoxicity using In Vitro Methods

Late stage failure of new therapies during clinical trials is a huge concern to the pharmaceutical industry […]

Read more...

Legal Privacy Site map Careers

This website is intended to assist industry participants, customers and employees to understand Cyprotex's global operations and ambitions.